Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

NCT02171676 ·Status: COMPLETED ·Phase: PHASE1

Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors

NCT00730821 ·Status: COMPLETED ·Phase: PHASE1

BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit

NCT02211872 ·Status: COMPLETED ·Phase: PHASE1

An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours

NCT02182206 ·Status: COMPLETED ·Phase: PHASE1

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

NCT00998296 ·Status: COMPLETED ·Phase: PHASE1

Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

NCT02211859 ·Status: COMPLETED ·Phase: PHASE1

A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

NCT02952248 ·Status: COMPLETED ·Phase: PHASE1

A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors

NCT07124117 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

NCT00618735 ·Status: COMPLETED ·Phase: PHASE1

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

NCT01951846 ·Status: COMPLETED ·Phase: PHASE1

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

NCT00715403 ·Status: COMPLETED ·Phase: PHASE1

Phase 1a/1b BGB-290 for Advanced Solid Tumors.

NCT02361723 ·Status: COMPLETED ·Phase: PHASE1

BI 811283 in Various Solid Tumours

NCT00701324 ·Status: COMPLETED ·Phase: PHASE1

Trial to Determine MTD of BI 836845 Administered Intravenously Once Every Three Weeks in Patients With Advanced Solid Tumours and Later a Weekly Dosing Schedule in Selected Tumour Types

NCT01317420 ·Status: COMPLETED ·Phase: PHASE1

Administration of BIIB028 to Subjects With Solid Tumors

NCT00725933 ·Status: COMPLETED ·Phase: PHASE1

Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors

NCT00345189 ·Status: COMPLETED ·Phase: PHASE1

A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread

NCT04147247 ·Status: COMPLETED ·Phase: PHASE1

A Study of BI 853520 in Patients With Various Types of Advanced or Metastatic Cancer

NCT01335269 ·Status: COMPLETED ·Phase: PHASE1

An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

NCT01206816 ·Status: COMPLETED ·Phase: PHASE1

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

NCT07186842 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours

NCT02182128 ·Status: COMPLETED ·Phase: PHASE1

Weekly BI 836880 in Patients With Advanced Solid Tumors

NCT02689505 ·Status: COMPLETED ·Phase: PHASE1

This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)

NCT03449381 ·Status: COMPLETED ·Phase: PHASE1

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

NCT02298387 ·Status: COMPLETED ·Phase: PHASE1

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated

NCT05327946 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1